SELLAS Life Sciences to Unveil SLS009 Findings at ASCO
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is stepping into the spotlight at the annual American Society of Clinical Oncology (ASCO) meeting, where they will share significant advancements in cancer research. The company, known for its innovative approach to developing cancer therapies, has announced that the preclinical efficacy of their candidate SLS009, a CDK9 inhibitor, will be showcased. This research targets ASXL1 mutated colorectal cancer cell lines, paving the way for new treatment frontiers.
Insight into the Poster Presentation
The presentation titled "In vitro efficacy of CDK9 inhibitor tambiciclib (SLS009) in ASXL1 mutated colorectal cancer cell lines" will be prominently featured at the conference. Attendees can look forward to this enlightening session on June 2, with detailed discussions from 1:30 PM to 4:30 PM CDT. The focus will be on developmental therapeutics and the biology of tumors, making it a pivotal opportunity for oncologists and researchers alike.
Key Presentation Details
- Abstract #: 3121
- Location: Hall A - Posters and Exhibits
- Poster Board #: 436
The complete text of the abstract is set to be released by ASCO ahead of the event, on a specific date that will enhance the anticipation surrounding the findings.
Current Research on SLS009
SLS009 is currently under investigation in an open-label, multi-center Phase 2 study. This trial aims to evaluate the safety, tolerability, and efficacy of SLS009 in combination with venetoclax and azacitidine, targeting acute myeloid leukemia (AML) patients harboring ASXL1 mutations. This specific subset of patients often faces poor prognoses, making the research even more critical. Early safety and efficacy data from this study looks promising, and researchers are also hopeful about identifying biomarkers that could enrich future trials.
What to Expect from the Study
As the study unfolds, it is poised to deliver invaluable insights into patient responses and the potential application of SLS009 across various cancers. The involvement of this innovative treatment illustrates SELLAS’ commitment to advancing cancer therapies and improving outcomes for patients facing dire diagnoses.
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences is on the cutting edge of cancer therapeutics, focusing not just on one type of cancer but crafting solutions applicable to a wide range of indications. The lead candidate, GPS, which is licensed from Memorial Sloan Kettering Cancer Center, targets the tumor-associated WT1 protein. This essential research aims at treating numerous hematologic malignancies and solid tumors effectively. In addition, SLS009 is viewed as a candidate that could redefine how CDK9 inhibitors are perceived in the oncology market, with reduced toxicity and heightened effectiveness, especially for patients with challenging cancer profiles.
Investor Relations
For those interested in learning more about SELLAS and their ongoing projects, our investor relations team is available. Bruce Mackle, the Managing Director at LifeSci Advisors, is ready to provide insight and updates about the company’s latest developments. Investors can reach out directly via email at SELLAS@lifesciadvisors.com.
Frequently Asked Questions
What is SLS009?
SLS009, also known as tambiciclib, is a CDK9 inhibitor currently being developed for the treatment of cancers with ASXL1 mutations.
When will the findings on SLS009 be presented?
The findings will be presented on June 2 during the ASCO Annual Meeting from 1:30 PM to 4:30 PM CDT.
What is the main focus of SELLAS Life Sciences?
SELLAS focuses on developing innovative cancer therapies, including novel treatments targeting various cancer indications.
How can one access the findings from the ASCO presentation?
Details on the findings will be available on ASCO's website after the presentation, along with the abstract text.
Who can be contacted for investor inquiries at SELLAS?
Bruce Mackle is the contact for investor inquiries, reachable via email at SELLAS@lifesciadvisors.com.
